Breast cancer (BC) continues to be the most common cancer in women and is responsible for almost 40,000 deaths per year. According to the VA Center for Women Veterans, women are the fastest growing subgroup of U.S. veterans and this number is expected to grow in the next 10 years. Therefore, as the population ages, VA health care will be in high demand by women veterans. This is because some of the same risk factors that are associated with poor prognosis in the general population are also found in the VA population. The VA also treats a moderately high volume of male BC and, unlike the declining mortality for female BC, death rates from male BC have not decreased. Compared with the general population, a higher proportion of the male and female BC patients in the VA system are African-American, relative to the private sector, and this population exhibits higher mortality and morbidity rates. Therefore, identifying effective therapeutic targets to treat these diverse groups of veterans is highly relevant to the VA patient care mission. The previous VA Merit funded project addressed questions about how breast cancers acquire hormone independence and become metastatic or spread throughout the body. We suspected that this type of tumor progression was controlled by a BC protein (RUNX2) that regulates expression of genes that promote growth and metastasis. We also proposed to discover compounds that would inhibit the ability of this factor to increase BC progression. We found that the RUNX2 factor promotes BC progression to a more aggressive, metastatic form by increasing glucose metabolism, inhibiting mitochondrial respiration, and reducing epithelial- specific gene expression, or differentiation. We also used novel drug screening methods and activity assays developed in the laboratory to characterize several compounds related to vitamin D that inhibited the RUNX2 factor and BC growth. Given these observations, in this VA Merit renewal application we propose the hypothesis that the RUNX2 factor can alter BC metabolism and inhibit cell differentiation while promoting tumor progression. We further propose that targeted inhibition of this factor using novel vitamin D derivatives will restore normal cell metabolism and differentiation, prevent further tumor progression, and inhibit BC growth. The goal of this proposal, therefore, is to perform a comprehensive but focused analysis of the relationship between RUNX2-mediated breast cancer growth and differentiation. RUNX2 may promote a metabolic progression favoring glycolysis and suppressing mitochondrial respiration. Several specific BC cell models and novel compounds that promote BC cell differentiation will be used to define the mechanisms regulating breast cancer progression and metastasis. The goals are to (1) define the RUNX2-regulated relationship between BC cell differentiation, metabolism, and progression, (2) define how Vitamin D3 prohormone regulates RUNX2 DNA binding and BC differentiation through its regulation of cell metabolism, and (3) determine the mechanisms regulating RUNX2 DNA binding and BC differentiation by oxidized variants of Vitamin D3. Many patients within the Veterans Administration health care system also suffer from lung, colorectal, and head/neck cancers, which are prevalent in elderly veterans who are smokers. Our study may provide insight into understanding the molecular pathways regulating these malignancies. Because the hypotheses we are testing are also relevant to how RUNX2 regulates vascular disease, therapeutic targeting strategies discovered in this study may have applicability and clinical relevance for other pathologies prevalent in the veteran population that are exacerbated by aging and smoking, such as cardiovascular disease. !
This proposal will address several key issues regulating breast cancer development that are relevant to Veteran's health. These include how breast epithelial cells lose their normal function and appearance and spread throughout the body. Changes in the expression of specific genes will be analyzed since these regulate the ability of breast cancers to escape from the primary tumor, leading to tumors that are largely untreatable. Both men and women veterans could benefit from studies that seek to understand how breast cancers become more aggressive. This is because some of the same risk factors that are associated with poor prognosis in the general population are also found in the VA population. Several new compounds that prevent or reverse this progression will be characterized and tested. The discovery of therapeutic strategies and specific agents that prevent or reverse breast cancer progression will increase our understanding of other diseases common in the VA population and will have a positive impact on the ability to treat breast cancer in the broader population.
|Kim, Myoung Sook; Gernapudi, Ramkishore; Choi, Eun Yong et al. (2017) Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget 8:70916-70940|
|Twum-Ampofo, Jeffrey; Fu, De-Xue; Passaniti, Antonino et al. (2016) Metabolic targets for potential prostate cancer therapeutics. Curr Opin Oncol 28:241-7|
|Li, Zhipeng; Yang, Zejia; Passaniti, Antonino et al. (2016) A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Oncotarget 7:31892-906|
|Choe, Moran; Brusgard, Jessica L; Chumsri, Saranya et al. (2015) The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J Cell Biochem 116:2210-26|
|Mochin, Maria T; Underwood, Karen F; Cooper, Brandon et al. (2015) Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells. Microvasc Res 97:55-64|
|Brusgard, Jessica L; Choe, Moran; Chumsri, Saranya et al. (2015) RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget 6:28132-50|
|Lillehoj, Erik P; Hyun, Sang Won; Feng, Chiguang et al. (2014) Human airway epithelia express catalytically active NEU3 sialidase. Am J Physiol Lung Cell Mol Physiol 306:L876-86|
|Miranda-Ribera, Alba; Passaniti, Antonino; Ceciliani, Fabrizio et al. (2014) ?1-acid glycoprotein disrupts capillary-like tube formation of human lung microvascular endothelia. Exp Lung Res 40:507-19|
|Lee, Chunsik; Liu, Anguo; Miranda-Ribera, Alba et al. (2014) NEU1 sialidase regulates the sialylation state of CD31 and disrupts CD31-driven capillary-like tube formation in human lung microvascular endothelia. J Biol Chem 289:9121-35|
|Underwood, Karen F; Mochin, Maria T; Brusgard, Jessica L et al. (2013) A quantitative assay to study protein:DNA interactions, discover transcriptional regulators of gene expression, and identify novel anti-tumor agents. J Vis Exp :|
Showing the most recent 10 out of 11 publications